Cell Therapeutics Will Pursue Xyotax Approval For Women With NSCLC

Despite having missed the primary endpoints in both STELLAR 3 and 4 trials, Cell Therapeutics plans to seek approval for Xyotax as first-line therapy for women with poor performance status, advanced non-small cell lung cancer.